MEDI2070 Shows Clinical Benefit in Crohn’s Disease

MEDI2070 Shows Clinical Benefit in Crohn’s Disease
During Digestive Disease Week (May 16-19) in Washington, D.C., Bruce E. Sands, MD, of the Division of Gastroenterology at the Icahn School of Medicine in Mount Sinai, New York presented results where a new monoclonal antibody called MEDI2070 (MedImmune) led to improvements in clinical outcomes in 121 patients with Crohn’s disease. Dr. Sands and colleagues investigated in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *